OTC Markets

OTCQB Certification

I, Stephen From, President and Chief Executive Officer of Eyegate Pharmaceuticals, Inc. ("the Company"), certify that:

a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (check one):
- ☒ Company is registered under Section 12(g) of the Exchange Act
- ☐ Company is relying on Exchange Act Rule 12g3-2(b)
- ☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
- ☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
- ☐ Company is reporting under Section 15(d) of the Exchange Act.
- ☐ Other (describe) _____

b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.

c. The Company Profile displayed on www.otcmarkets.com is current and complete as of April 15, 2015 and includes the total shares outstanding, authorized, and in the public float as of that date.

d. The following is a complete list of attorney(s) and law firm(s) who advised or assisted in the preparation of the Company's most recent annual report, including in-house counsel: (If no attorney assisted in putting together the disclosure, indicate the person or persons who prepared the disclosure and their relationship to the company.)

Burns & Levinson LLP, 125 Summer Street, Boston, MA

e. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, or other related services to the Company including promotion of the Company or its securities:

IR Firm: The Ruth Group, 757 Third Avenue, New York NY 10017
IPO Underwriter: Aegis Capital Corp., 810 Seventh Avenue, 18th Floor, New York, NY 10019
IPO Underwriter: Chardan Capital Markets, LLC, 17 State Street, Suite 1600, New York, NY 10004

f. Listed below are the names, legal addresses and % of shares owned by all Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities). If any of the beneficial shareholders are corporate shareholders, the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders must also be included.

Name	Address (City and State only)	% Shares Owned
Stephen From	473 Chestnut Hill Avenue Brookline, MA 02445	5.2* ^
Paul Chaney	13 McGregor Avenue Mt. Arlington, NJ 07856	1.6* ^
Morton Goldberg	3607 Anton Farms Road Baltimore, MD 21208	0.6* ^
Praveen Tyle	67 Lenox Hill Drive Spring, TX 77382	0.6* ^
Thomas Balland	41 rue de l'Echiquier 75010 Paris, France	24.2* ** ^
Thomas E. Hancock	6 Mast Hill Road Hingham, MA 02043	0.1* ^

Bernard Malfroy-Camine	67 Crosby Street Arlington, MA 02474	0.2* ^
[Continued on Additional Page]		

Date: April 16, 2015

Name of Certifying CEO or CFO: Stephen From

Title: President and Chief Executive Officer

Signature: /s/ Stephen From
(Digital Signatures should appear as "/s/ [OFFICER NAME]")

OTC Markets

Additional Page

Name	Address (City and State only)	% Shares Owned
Mounia Chaoui	3 Avenue Gutenberg Puteaux, France 92800	0.1* ^
Michael Manzo	70 Neptune Street Beverly, MA 01915	0.9* ^
Entities affiliated with Ventech SA (*Alain Caffi and Jean Bourcereau, as directors of Ventech SA, have voting and investment power*)	47, avenue de l'Opéra Paris, France 75002	43.2* ^^
Entities affiliated with IPSA (*Jean-Michel Paulhac and Thomas Balland, as directors of IPSA, have voting and investment power*)	10 rue de la Paix, Paris, France 75002	24.1* ^^
Natixis Private Equity (*Dominique Sabassier, as general manager of Natixis Private Equity, has voting and investment power*)	5 – 7, rue de Monttessuy 75340 Paris cedex 07 France	11.5* ^^

* Percentage of shares beneficially owned as of March 27, 2015.
** Percentage includes 1,549,650 shares beneficially owned as a director of IPSA.
^ Percentage includes shares issuable pursuant to stock options exercisable within 60 days of March 27, 2015.
^^ Percentage includes shares issuable upon exercise of warrants.